AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Indaptus Therapeutics Statistics
Share Statistics
Indaptus Therapeutics has 12.01M shares outstanding. The number of shares has increased by 40.7% in one year.
Shares Outstanding | 12.01M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 17.82% |
Owned by Institutions (%) | n/a |
Shares Floating | 9.25M |
Failed to Deliver (FTD) Shares | 582 |
FTD / Avg. Volume | 0.49% |
Short Selling Information
The latest short interest is 138.70K, so 1.15% of the outstanding shares have been sold short.
Short Interest | 138.70K |
Short % of Shares Out | 1.15% |
Short % of Float | 1.5% |
Short Ratio (days to cover) | 0.54 |
Valuation Ratios
The PE ratio is -0.96 and the forward PE ratio is -0.83.
PE Ratio | -0.96 |
Forward PE | -0.83 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | 1.22 |
P/FCF Ratio | -1.1 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Indaptus Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.05, with a Debt / Equity ratio of 0.
Current Ratio | 5.05 |
Quick Ratio | 5.05 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.28% and return on capital (ROIC) is -133.68%.
Return on Equity (ROE) | -1.28% |
Return on Assets (ROA) | -1.03% |
Return on Capital (ROIC) | -133.68% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.20M |
Employee Count | 7 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -49.15% in the last 52 weeks. The beta is 1.13, so Indaptus Therapeutics 's price volatility has been higher than the market average.
Beta | 1.13 |
52-Week Price Change | -49.15% |
50-Day Moving Average | 1.01 |
200-Day Moving Average | 1.72 |
Relative Strength Index (RSI) | 44.14 |
Average Volume (20 Days) | 117.74K |
Income Statement
Revenue | n/a |
Gross Profit | -1.28K |
Operating Income | -16.38M |
Net Income | -15.42M |
EBITDA | -16.38M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.84 |
Balance Sheet
The company has 13.36M in cash and 175.05K in debt, giving a net cash position of 13.19M.
Cash & Cash Equivalents | 13.36M |
Total Debt | 175.05K |
Net Cash | 13.19M |
Retained Earnings | -45.42M |
Total Assets | 8.24M |
Working Capital | 5.40M |
Cash Flow
In the last 12 months, operating cash flow was -13.41M and capital expenditures 0, giving a free cash flow of -13.41M.
Operating Cash Flow | -13.41M |
Capital Expenditures | 0 |
Free Cash Flow | -13.41M |
FCF Per Share | -1.6 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
INDP does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -204.44% |
FCF Yield | -123.98% |
Analyst Forecast
The average price target for INDP is $8.5, which is 844.4% higher than the current price. The consensus rating is "Buy".
Price Target | $8.5 |
Price Target Difference | 844.4% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Stock Splits
The last stock split was on Jul 27, 2021. It was a backward split with a ratio of 1:4.
Last Split Date | Jul 27, 2021 |
Split Type | backward |
Split Ratio | 1:4 |
Scores
Altman Z-Score | -11.88 |
Piotroski F-Score | 2 |